HomeNP5 • ETR
add
Newron Pharmaceuticals SpA
Nakaraang pagsara
€7.63
Sakop ng araw
€7.53 - €7.77
Sakop ng taon
€6.03 - €11.90
Market cap
142.54M CHF
Average na Volume
4.44K
P/E ratio
-
Dividend yield
-
Primary exchange
SWX
Mga balita tungkol sa merkado
Bloomberg.com
1 oras ang nakalipas
Vanguard’s VOO, World’s Biggest ETF, Nabs Record Flows in April
1.19%
1.29%
Mga Financial
Income Statement
Kita
Net na kita
| (EUR) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 23.99M | 1,246.70% |
Gastos sa pagpapatakbo | 7.06M | 29.77% |
Net na kita | 12.70M | 373.88% |
Net profit margin | 52.94 | 120.34% |
Kita sa bawat share | — | — |
EBITDA | 16.93M | 564.71% |
Aktuwal na % ng binabayarang buwis | 17.90% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (EUR) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 9.83M | -22.01% |
Kabuuang asset | 63.91M | 147.07% |
Kabuuang sagutin | 62.45M | 11.97% |
Kabuuang equity | 1.46M | — |
Natitirang share | 19.96M | — |
Presyo para makapag-book | 109.00 | — |
Return on assets | 66.22% | — |
Return on capital | 81.50% | — |
Cash Flow
Net change in cash
| (EUR) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 12.70M | 373.88% |
Cash mula sa mga operasyon | -4.39M | -93.65% |
Cash mula sa pag-invest | 574.50K | -64.72% |
Cash mula sa financing | 3.34M | 7,124.21% |
Net change in cash | -482.00K | 29.89% |
Malayang cash flow | 9.99M | 451.87% |
Tungkol
CEO
Itinatag
1999
Website
Mga Empleyado
22
